Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

The Efficacy, Tolerability and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double-blind, Placebo-controlled, Randomized Clinical Trial.

Dakin P, DiMartino SJ, Gao H, Maloney J, Kivitz AJ, Schnitzer TJ, Stahl N, Yancopoulos GD, Geba GP.

Arthritis Rheumatol. 2019 Jun 17. doi: 10.1002/art.41012. [Epub ahead of print]

PMID:
31207169
2.

Deep Convolutional Neural Networks for the Prediction of Molecular Properties: Challenges and Opportunities Connected to the Data.

Ståhl N, Falkman G, Karlsson A, Mathiason G, Boström J.

J Integr Bioinform. 2018 Dec 5;16(1). pii: /j/jib.2019.16.issue-1/jib-2018-0065/jib-2018-0065.xml. doi: 10.1515/jib-2018-0065.

PMID:
30517077
3.

Does time from diagnostic CT until surgical evacuation affect outcome in patients with chronic subdural hematoma?

Zolfaghari S, Ståhl N, Nittby Redebrandt H.

Acta Neurochir (Wien). 2018 Sep;160(9):1703-1709. doi: 10.1007/s00701-018-3620-y. Epub 2018 Jul 24.

4.

Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets.

de Wit E, Feldmann F, Okumura A, Horne E, Haddock E, Saturday G, Scott D, Erlandson KJ, Stahl N, Lipsich L, Kyratsous CA, Feldmann H.

Antiviral Res. 2018 Aug;156:64-71. doi: 10.1016/j.antiviral.2018.06.006. Epub 2018 Jun 7.

PMID:
29885377
5.

Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates.

Pascal KE, Dudgeon D, Trefry JC, Anantpadma M, Sakurai Y, Murin CD, Turner HL, Fairhurst J, Torres M, Rafique A, Yan Y, Badithe A, Yu K, Potocky T, Bixler SL, Chance TB, Pratt WD, Rossi FD, Shamblin JD, Wollen SE, Zelko JM, Carrion R Jr, Worwa G, Staples HM, Burakov D, Babb R, Chen G, Martin J, Huang TT, Erlandson K, Willis MS, Armstrong K, Dreier TM, Ward AB, Davey RA, Pitt MLM, Lipsich L, Mason P, Olson W, Stahl N, Kyratsous CA.

J Infect Dis. 2018 Nov 22;218(suppl_5):S612-S626. doi: 10.1093/infdis/jiy285.

6.

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.

Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, Zhu H, Hamilton JD, Swanson BN, Khan A, Chao J, Staudinger H, Pirozzi G, Antoni C, Amin N, Ruddy M, Akinlade B, Graham NMH, Stahl N, Yancopoulos GD, Teper A.

N Engl J Med. 2018 Jun 28;378(26):2475-2485. doi: 10.1056/NEJMoa1804093. Epub 2018 May 21.

7.

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.

Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A.

N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21.

8.

Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement.

Orengo JM, Radin AR, Kamat V, Badithe A, Ben LH, Bennett BL, Zhong S, Birchard D, Limnander A, Rafique A, Bautista J, Kostic A, Newell D, Duan X, Franklin MC, Olson W, Huang T, Gandhi NA, Lipsich L, Stahl N, Papadopoulos NJ, Murphy AJ, Yancopoulos GD.

Nat Commun. 2018 Apr 12;9(1):1421. doi: 10.1038/s41467-018-03636-8.

9.

ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia.

Gaudet D, Gipe DA, Pordy R, Ahmad Z, Cuchel M, Shah PK, Chyu KY, Sasiela WJ, Chan KC, Brisson D, Khoury E, Banerjee P, Gusarova V, Gromada J, Stahl N, Yancopoulos GD, Hovingh GK.

N Engl J Med. 2017 Jul 20;377(3):296-297. doi: 10.1056/NEJMc1705994. No abstract available.

PMID:
28723334
10.

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.

Dewey FE, Gusarova V, Dunbar RL, O'Dushlaine C, Schurmann C, Gottesman O, McCarthy S, Van Hout CV, Bruse S, Dansky HM, Leader JB, Murray MF, Ritchie MD, Kirchner HL, Habegger L, Lopez A, Penn J, Zhao A, Shao W, Stahl N, Murphy AJ, Hamon S, Bouzelmat A, Zhang R, Shumel B, Pordy R, Gipe D, Herman GA, Sheu WHH, Lee IT, Liang KW, Guo X, Rotter JI, Chen YI, Kraus WE, Shah SH, Damrauer S, Small A, Rader DJ, Wulff AB, Nordestgaard BG, Tybjærg-Hansen A, van den Hoek AM, Princen HMG, Ledbetter DH, Carey DJ, Overton JD, Reid JG, Sasiela WJ, Banerjee P, Shuldiner AR, Borecki IB, Teslovich TM, Yancopoulos GD, Mellis SJ, Gromada J, Baras A.

N Engl J Med. 2017 Jul 20;377(3):211-221. doi: 10.1056/NEJMoa1612790. Epub 2017 May 24.

11.

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.

Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemény L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B.

Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4.

PMID:
28478972
12.

Antidrug Antibodies in Patients Treated with Alirocumab.

Roth EM, Goldberg AC, Catapano AL, Torri A, Yancopoulos GD, Stahl N, Brunet A, Lecorps G, Colhoun HM.

N Engl J Med. 2017 Apr 20;376(16):1589-90. doi: 10.1056/NEJMc1616623. Epub 2017 Mar 17. No abstract available.

13.

An Exploratory Study to Assess Individual and Structural Level Barriers Associated With Poor Retention and Re-engagement in Care Among Persons Living With HIV/AIDS.

Colasanti J, Stahl N, Farber EW, Del Rio C, Armstrong WS.

J Acquir Immune Defic Syndr. 2017 Feb 1;74 Suppl 2:S113-S120. doi: 10.1097/QAI.0000000000001242.

14.

Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study.

Dewey FE, Murray MF, Overton JD, Habegger L, Leader JB, Fetterolf SN, O'Dushlaine C, Van Hout CV, Staples J, Gonzaga-Jauregui C, Metpally R, Pendergrass SA, Giovanni MA, Kirchner HL, Balasubramanian S, Abul-Husn NS, Hartzel DN, Lavage DR, Kost KA, Packer JS, Lopez AE, Penn J, Mukherjee S, Gosalia N, Kanagaraj M, Li AH, Mitnaul LJ, Adams LJ, Person TN, Praveen K, Marcketta A, Lebo MS, Austin-Tse CA, Mason-Suares HM, Bruse S, Mellis S, Phillips R, Stahl N, Murphy A, Economides A, Skelding KA, Still CD, Elmore JR, Borecki IB, Yancopoulos GD, Davis FD, Faucett WA, Gottesman O, Ritchie MD, Shuldiner AR, Reid JG, Ledbetter DH, Baras A, Carey DJ.

Science. 2016 Dec 23;354(6319). pii: aaf6814. doi: 10.1126/science.aaf6814.

PMID:
28008009
15.

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators.

N Engl J Med. 2016 Dec 15;375(24):2335-2348. Epub 2016 Sep 30.

16.

Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes.

MacDonald DA, Martin J, Muthusamy KK, Luo JK, Pyles E, Rafique A, Huang T, Potocky T, Liu Y, Cao J, Bono F, Delesque N, Savi P, Francis J, Amirkhosravi A, Meyer T, Romano C, Glinka M, Yancopoulos GD, Stahl N, Wiegand SJ, Papadopoulos N.

Angiogenesis. 2016 Jul;19(3):389-406. doi: 10.1007/s10456-016-9515-8. Epub 2016 May 27.

17.

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.

Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, Eckert L, Graham NM, Stahl N, Yancopoulos GD, Louis-Tisserand M, Teper A.

Lancet. 2016 Jul 2;388(10039):31-44. doi: 10.1016/S0140-6736(16)30307-5. Epub 2016 Apr 27.

PMID:
27130691
18.

Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes.

Ramanathan A, Gusarova V, Stahl N, Gurnett-Bander A, Kyratsous CA.

PLoS One. 2016 Apr 26;11(4):e0154498. doi: 10.1371/journal.pone.0154498. eCollection 2016.

19.

Early postoperative haematomas in neurosurgery.

Nittby HR, Maltese A, Ståhl N.

Acta Neurochir (Wien). 2016 May;158(5):837-46. doi: 10.1007/s00701-016-2778-4. Epub 2016 Mar 28.

PMID:
27020442
20.

Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial.

Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, Hellings P, Jiao L, Wang L, Evans RR, Pirozzi G, Graham NM, Swanson B, Hamilton JD, Radin A, Gandhi NA, Stahl N, Yancopoulos GD, Sutherland ER.

JAMA. 2016 Feb 2;315(5):469-79. doi: 10.1001/jama.2015.19330.

PMID:
26836729
21.

A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.

Smith EJ, Olson K, Haber LJ, Varghese B, Duramad P, Tustian AD, Oyejide A, Kirshner JR, Canova L, Menon J, Principio J, MacDonald D, Kantrowitz J, Papadopoulos N, Stahl N, Yancopoulos GD, Thurston G, Davis S.

Sci Rep. 2015 Dec 11;5:17943. doi: 10.1038/srep17943.

22.

Targeting key proximal drivers of type 2 inflammation in disease.

Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD.

Nat Rev Drug Discov. 2016 Jan;15(1):35-50. doi: 10.1038/nrd4624. Epub 2015 Oct 16. Review.

PMID:
26471366
23.

Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.

Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, Soong W, Worm M, Szepietowski JC, Sofen H, Kawashima M, Wu R, Weinstein SP, Graham NM, Pirozzi G, Teper A, Sutherland ER, Mastey V, Stahl N, Yancopoulos GD, Ardeleanu M.

Lancet. 2016 Jan 2;387(10013):40-52. doi: 10.1016/S0140-6736(15)00388-8. Epub 2015 Oct 8.

PMID:
26454361
24.

Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody.

Hopkins PN, Defesche J, Fouchier SW, Bruckert E, Luc G, Cariou B, Sjouke B, Leren TP, Harada-Shiba M, Mabuchi H, Rabès JP, Carrié A, van Heyningen C, Carreau V, Farnier M, Teoh YP, Bourbon M, Kawashiri MA, Nohara A, Soran H, Marais AD, Tada H, Abifadel M, Boileau C, Chanu B, Katsuda S, Kishimoto I, Lambert G, Makino H, Miyamoto Y, Pichelin M, Yagi K, Yamagishi M, Zair Y, Mellis S, Yancopoulos GD, Stahl N, Mendoza J, Du Y, Hamon S, Krempf M, Swergold GD.

Circ Cardiovasc Genet. 2015 Dec;8(6):823-31. doi: 10.1161/CIRCGENETICS.115.001129. Epub 2015 Sep 15.

25.

Reply to Dimitrov et al.: VelociSuite technologies are a foundation for rapid therapeutic antibody development.

Kyratsous CA, Olson W, Stahl N.

Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):E5116. doi: 10.1073/pnas.1513935112. Epub 2015 Aug 28. No abstract available.

26.

Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.

Brown DM, Schmidt-Erfurth U, Do DV, Holz FG, Boyer DS, Midena E, Heier JS, Terasaki H, Kaiser PK, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Korobelnik JF.

Ophthalmology. 2015 Oct;122(10):2044-52. doi: 10.1016/j.ophtha.2015.06.017. Epub 2015 Jul 18.

PMID:
26198808
27.

Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection.

Pascal KE, Coleman CM, Mujica AO, Kamat V, Badithe A, Fairhurst J, Hunt C, Strein J, Berrebi A, Sisk JM, Matthews KL, Babb R, Chen G, Lai KM, Huang TT, Olson W, Yancopoulos GD, Stahl N, Frieman MB, Kyratsous CA.

Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8738-43. doi: 10.1073/pnas.1510830112. Epub 2015 Jun 29.

28.

Aberrant immunostaining pattern of the CD24 glycoprotein in clinical samples and experimental models of pediatric medulloblastomas.

Sandén E, Dyberg C, Krona C, Visse E, Carén H, Northcott PA, Kool M, Ståhl N, Persson A, Englund E, Johnsen JI, Siesjö P, Darabi A.

J Neurooncol. 2015 May;123(1):1-13. doi: 10.1007/s11060-015-1758-5. Epub 2015 Mar 29.

PMID:
25820321
29.

Self-reported childhood maltreatment, lifelong traumatic events and mental disorders in fibromyalgia syndrome: a comparison of US and German outpatients.

Häuser W, Hoffmann EM, Wolfe F, Worthing AB, Stahl N, Rothenberg R, Walitt B.

Clin Exp Rheumatol. 2015 Jan-Feb;33(1 Suppl 88):S86-92. Epub 2015 Mar 18.

30.

An Adaptation of Motivational Interviewing Increases Quit Attempts in Smokers With Serious Mental Illness.

Steinberg ML, Williams JM, Stahl NF, Budsock PD, Cooperman NA.

Nicotine Tob Res. 2016 Mar;18(3):243-50. doi: 10.1093/ntr/ntv043. Epub 2015 Mar 5.

31.

Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.

Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, Rohane P, van Hoogstraten H, Garg A, Fan C, van Adelsberg J, Weinstein SP, Graham NM, Stahl N, Yancopoulos GD, Huizinga TW, van der Heijde D.

Arthritis Rheumatol. 2015 Jun;67(6):1424-37. doi: 10.1002/art.39093.

32.

Intravitreal aflibercept for diabetic macular edema.

Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, Midena E, Kaiser PK, Terasaki H, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Brown DM.

Ophthalmology. 2014 Nov;121(11):2247-54. doi: 10.1016/j.ophtha.2014.05.006. Epub 2014 Jul 8.

PMID:
25012934
33.

Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.

Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, Ardeleanu M, Weinstein SP, Pirozzi G, Guttman-Yassky E, Suárez-Fariñas M, Hager MD, Stahl N, Yancopoulos GD, Radin AR.

N Engl J Med. 2014 Jul 10;371(2):130-9. doi: 10.1056/NEJMoa1314768.

34.

Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN).

Sieper J, Braun J, Kay J, Badalamenti S, Radin AR, Jiao L, Fiore S, Momtahen T, Yancopoulos GD, Stahl N, Inman RD.

Ann Rheum Dis. 2015 Jun;74(6):1051-7. doi: 10.1136/annrheumdis-2013-204963. Epub 2014 Feb 18.

35.

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.

Huizinga TW, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S, Huang X, Yancopoulos GD, Stahl N, Genovese MC.

Ann Rheum Dis. 2014 Sep;73(9):1626-34. doi: 10.1136/annrheumdis-2013-204405. Epub 2013 Dec 2.

36.

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.

Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenberg C, Sandbrink R, Heier JS.

Ophthalmology. 2014 Jan;121(1):193-201. doi: 10.1016/j.ophtha.2013.08.011. Epub 2013 Sep 29.

PMID:
24084500
37.

Bedside diagnosis of mitochondrial dysfunction after malignant middle cerebral artery infarction.

Nielsen TH, Schalén W, Ståhl N, Toft P, Reinstrup P, Nordström CH.

Neurocrit Care. 2014 Aug;21(1):35-42. doi: 10.1007/s12028-013-9875-5.

PMID:
23860668
38.

Dupilumab in persistent asthma with elevated eosinophil levels.

Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B, Hamilton J, Ming JE, Radin A, Stahl N, Yancopoulos GD, Graham N, Pirozzi G.

N Engl J Med. 2013 Jun 27;368(26):2455-66. doi: 10.1056/NEJMoa1304048. Epub 2013 May 21.

39.

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups.

Ophthalmology. 2012 Dec;119(12):2537-48. doi: 10.1016/j.ophtha.2012.09.006. Epub 2012 Oct 17. Erratum in: Ophthalmology. 2013 Jan;120(1):209-10.

PMID:
23084240
40.

Recirculation usually precedes malignant edema in middle cerebral artery infarcts.

Nielsen TH, Ståhl N, Schalén W, Reinstrup P, Toft P, Nordström CH.

Acta Neurol Scand. 2012 Dec;126(6):404-10. doi: 10.1111/j.1600-0404.2012.01664.x. Epub 2012 Apr 12.

PMID:
22494199
41.

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, Lisbon E, Gutierrez M, Webb C, Wu R, Du Y, Kranz T, Gasparino E, Swergold GD.

N Engl J Med. 2012 Mar 22;366(12):1108-18. doi: 10.1056/NEJMoa1105803.

42.

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.

Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ.

Angiogenesis. 2012 Jun;15(2):171-85. doi: 10.1007/s10456-011-9249-6. No abstract available.

43.

Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial.

Schumacher HR Jr, Sundy JS, Terkeltaub R, Knapp HR, Mellis SJ, Stahl N, Yancopoulos GD, Soo Y, King-Davis S, Weinstein SP, Radin AR; 0619 Study Group.

Arthritis Rheum. 2012 Mar;64(3):876-84. doi: 10.1002/art.33412.

44.

Exploring transitions within a project-based Housing First setting: qualitative evaluation and practice implications.

Collins SE, Clifasefi SL, Andrasik MP, Dana EA, Stahl N, Kirouac M, Welbaum C, King M, Malone DK.

J Health Care Poor Underserved. 2012 Nov;23(4):1678-97. doi: 10.1353/hpu.2012.0187.

45.

Where harm reduction meets housing first: exploring alcohol's role in a project-based housing first setting.

Collins SE, Clifasefi SL, Dana EA, Andrasik MP, Stahl N, Kirouac M, Welbaum C, King M, Malone DK.

Int J Drug Policy. 2012 Mar;23(2):111-9. doi: 10.1016/j.drugpo.2011.07.010. Epub 2011 Aug 17.

46.

The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing.

Heier JS, Boyer D, Nguyen QD, Marcus D, Roth DB, Yancopoulos G, Stahl N, Ingerman A, Vitti R, Berliner AJ, Yang K, Brown DM; CLEAR-IT 2 Investigators.

Ophthalmology. 2011 Jun;118(6):1098-106. doi: 10.1016/j.ophtha.2011.03.020. Erratum in: Ophthalmology. 2011 Sep;118(9):1700.

PMID:
21640258
47.

Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration.

Brown DM, Heier JS, Ciulla T, Benz M, Abraham P, Yancopoulos G, Stahl N, Ingerman A, Vitti R, Berliner AJ, Yang K, Nguyen QD; CLEAR-IT 2 Investigators.

Ophthalmology. 2011 Jun;118(6):1089-97. doi: 10.1016/j.ophtha.2011.02.039.

PMID:
21640257
48.

[In spite of correct diagnosis of total brain infarction the organ donation was interrupted].

Isegran M, Säveland H, Ståhl N, Schalén W, Reinstrup P.

Lakartidningen. 2011 Jan 12-18;108(1-2):31-3. Swedish. No abstract available.

PMID:
21365811
49.

Rilonacept--CAPS and beyond.

Stahl N, Radin A, Mellis S.

Ann N Y Acad Sci. 2009 Dec;1182:124-34. doi: 10.1111/j.1749-6632.2009.05074.x. Review.

PMID:
20074281
50.

Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.

Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, Weinstein SP, Belomestnov P, Yancopoulos GD, Stahl N, Mellis SJ.

Arthritis Rheum. 2008 Aug;58(8):2443-52. doi: 10.1002/art.23687.

Supplemental Content

Support Center